<DOC>
	<DOCNO>NCT01004770</DOCNO>
	<brief_summary>This non-randomized dose-escalating study evaluate safety tolerability GE-145 four different dose level assessment clinical laboratory , vital sign , physical examination , electrocardiogram ( ECGs ) frequency intensity adverse event ( AEs ) . It characterize pharmacokinetic property GE-145 evaluation serum urine . It evaluate radiographic density region interest ( ROI ) overall diagnostic quality follow administration GE-145 .</brief_summary>
	<brief_title>Single Dose Safety , Tolerance Pharmacokinetic Study Healthy Volunteers Undergoing Contrast-enhanced Abdominal Computed Tomography ( CT )</brief_title>
	<detailed_description />
	<criteria>Healthy male females 18 60 year age . For woman either surgically sterile postmenopausal , enrollment study without pregnancy test screening allow . For woman childbearing potential , result serum urine HCG pregnancy test ( result know day IMP administration ) must negative . Subjects able willing comply study procedure sign inform consent . Known history reaction iodinatedbased contrast agent multiple allergy ( i.e . food , pet , medication , etc ) . Subjects receive medication use iodinate contrast agent contraindicate ( i.e.. metformin ) . Subjects suspicion diagnosis hyperthyroidism . Women breastfeed screen and/or enrolment period . Usage nonFDAapproved pharmaceutical therapy within 30 day prior screen enrolment another clinical study within 30 day prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>CECT - Contrast-enhanced computed tomography</keyword>
	<keyword>HCG - Human Chorionic Gonadotropin</keyword>
	<keyword>HU - Hounsfield Units</keyword>
	<keyword>Patient Safety</keyword>
	<keyword>Tolerance</keyword>
	<keyword>Pharmacokinetic</keyword>
</DOC>